Wegovy first week results: what to realistically expect

What the STEP 1 trial data actually tells us about early results

The STEP 1 trial enrolled 1,961 adults with obesity and tracked them for 68 weeks on semaglutide 2.4mg weekly. The headline finding (around 15% average body-weight reduction) is real and clinically significant. But that number accumulated gradually. Participants started at 0.25mg, the same starter dose used today, and the trial's dose escalation took approximately 16 weeks before reaching 2.4mg. In week one, nobody was on a therapeutic maintenance dose. The body was receiving the lowest possible amount, primarily to reduce the chance of nausea and other gastrointestinal effects.

This matters because many people measure their weight on day seven and feel disappointed. The evidence does not support expecting visible loss that early. What the data does show is that appetite changes can begin sooner: some participants reported reduced hunger in the first fortnight, even before meaningful weight change registered on the scales. That biological signal (feeling full on less food, thinking about eating less often) is the mechanism beginning to work, even when the number on the scales has barely shifted. If you want to understand how long Wegovy typically takes to produce noticeable results, the honest answer involves weeks rather than days.

Common physical experiences in the first seven days

The NHS medicines page for semaglutide lists nausea, vomiting, diarrhoea, constipation, stomach discomfort, burping, and fatigue among the most frequently reported side effects, and they tend to be most noticeable in the early weeks of treatment or after a dose increase. Week one sits squarely in that window.

Nausea is the most talked-about. It is typically mild to moderate, often peaks a day or two after the injection, and settles within a few days for most people. Eating smaller portions and avoiding rich or fatty meals helps. Staying well hydrated matters too. Some people feel genuinely full after half a plate of food, which feels strange before it feels like progress. A smaller number experience headache or light tiredness in the first few days. These experiences are common enough that they feature in the patient information leaflet, and rare enough to be serious at this dose that most people complete the first week without interruption.

If you want a detailed account of what the second week tends to bring, the second-week expectations guide covers the shift many people notice as their system adjusts. Most clinicians and patients agree the first two weeks are the hardest, and that it eases from there.

Why the scale in week one can be misleading

A kilogram or two of apparent loss in week one is usually water. Reduced carbohydrate intake from eating less naturally depletes glycogen stores, which hold water, so the scales can drop in a way that has nothing to do with fat loss. Some people see nothing at all, because they are eating slightly less but still retaining fluid. Neither reading tells you much about how treatment will progress.

The clinical trajectory is more instructive. The STEP 1 data shows that average weight loss at four weeks was modest; at 12 weeks it became more apparent; and it continued building toward the 15% figure at 68 weeks. Thinking about your results on a monthly basis (rather than weekly, and certainly not daily) aligns much better with the pharmacology. A look at what Wegovy typically produces in the first month gives a more meaningful checkpoint than day seven alone. For people curious about the week-by-week picture as it unfolds, there are also detailed breakdowns covering week two and week three results.

One practical note: trying to weigh yourself at a consistent time (first thing in the morning before breakfast, not after a big Saturday lunch) removes some of the noise from daily fluctuation. It is one of those small habits that makes the data you collect at home actually useful.

Starting Wegovy through a regulated UK service

Wegovy is a prescription-only medicine. The only legal route to it in the UK is through a clinical assessment by a qualified prescriber, whether via a GP, an NHS specialist service, or a regulated private service like Wegovy through nume. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber (not automated software) and the pharmacy is registered with the General Pharmaceutical Council (registration number 9012878, verifiable on the GPhC register).

Understanding what week one genuinely looks like is part of what our prescribers explain at consultation, alongside how the titration schedule works, what to do if side effects are troublesome, and what a realistic four to six month trajectory might involve for you personally. The first week's results are not the story. They are the opening line. If you are ready to understand the full picture, you can start your free consultation and speak to our clinical team. For those researching the broader treatment landscape before committing, the weight-loss treatment overview sets out all the options clearly.